Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Genmab and partner AbbVie (ABBV) are seeing continued good traction of Epkinly, and Genmab says that physicians are providing good feedback since last summer’s approval for relapsed/refractory ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...

and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. Breaking Down Genmab's Financial Performance ...

Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it. The Copenhagen, Denmark, biotechnology company said ...

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it. The ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

and Epkinly (partnered with AbbVie) for the treatment of diffuse large B-cell lymphoma received regulatory approvals in the United States, European Union, and Japan in 2023. We believe Genmab's ...

With the GEN3014 now removed from the firm’s forecasts, RBC analysts made slight estimate changes in the mid-term and lowered its price target on Genmab shares to DKK 2,300 from DKK 2,400.

Highlights from Woyach, professor in the division of hematology at The Ohio State University, include a study that evaluated epcoritamab (Epkinly; Genmab, AbbVie) monotherapy, and another that ...